Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H21NO2 |
Molecular Weight | 247.3327 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1(CCN(C)CC1)C2=CC=CC=C2
InChI
InChIKey=XADCESSVHJOZHK-UHFFFAOYSA-N
InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
Molecular Formula | C15H21NO2 |
Molecular Weight | 247.3327 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.pbm.va.gov/clinicalguidance/criteriaforuse/MeperidineCriteriaforUse.pdf | https://www.drugs.com/pro/meperidine.html
Curator's Comment: description was created based on several sources, including:
http://www.pbm.va.gov/clinicalguidance/criteriaforuse/MeperidineCriteriaforUse.pdf | https://www.drugs.com/pro/meperidine.html
Pethidine, also known as meperidine and Demerol, a narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Meperidine is an opioid agonist with multiple actions qualitatively similar to those of morphine. Most common adverse reactions were lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Pethidine has serious interactions that can be dangerous with monoamine oxidase inhibitors (e.g., furazolidone, isocarboxazid, moclobemide, phenelzine, procarbazine, selegiline, tranylcypromine). Pethidine can interact with muscle relaxants, some antidepressants, benzodiazepines, and ethanol.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21215785 |
450.1 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DEMEROL Approved UseFor the relief of moderate to severe pain. For preoperative medication. For support of anesthesia. For obstetrical analgesia. Launch Date1942 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
196 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2891328/ |
30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MEPERIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19.6 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2891328/ |
30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MEPERIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
124 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2891328/ |
30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MEPERIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
10 g single, oral Overdose |
unknown, 17 years |
Other AEs: Respiratory depression, Hypotension... Other AEs: Respiratory depression (1 patient) Sources: Hypotension (1 patient) Tremor (1 patient) Hyperreflexia (1 patient) Myoclonus (1 patient) |
50 mg single, intrathecal Dose: 50 mg Route: intrathecal Route: single Dose: 50 mg Sources: |
unknown, 24 - 81 years Health Status: unknown Age Group: 24 - 81 years Sex: F Sources: |
Other AEs: Respiratory depression... |
1000 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 1000 mg, 1 times / day Route: intramuscular Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 37 years |
Disc. AE: Muscle twitching, Tremor... AEs leading to discontinuation/dose reduction: Muscle twitching (1 patient) Sources: Tremor (1 patient) |
600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years |
Other AEs: Jitteriness, Hallucinations... Other AEs: Jitteriness (3 patients) Sources: Hallucinations (3 patients) Seizures (3 patients) |
50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperreflexia | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Hypotension | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Myoclonus | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Respiratory depression | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Tremor | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Respiratory depression | 2 patients | 50 mg single, intrathecal Dose: 50 mg Route: intrathecal Route: single Dose: 50 mg Sources: |
unknown, 24 - 81 years Health Status: unknown Age Group: 24 - 81 years Sex: F Sources: |
Muscle twitching | 1 patient Disc. AE |
1000 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 1000 mg, 1 times / day Route: intramuscular Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 37 years |
Tremor | 1 patient Disc. AE |
1000 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 1000 mg, 1 times / day Route: intramuscular Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 37 years |
Hallucinations | 3 patients | 600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years |
Jitteriness | 3 patients | 600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years |
Seizures | 3 patients | 600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years |
Withdrawal syndrome neonatal | 50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Withdrawal syndrome neonatal | 50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Withdrawal syndrome neonatal | 50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Addiction | 50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Addiction | 50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Addiction | 50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Withdrawal syndrome neonatal | 10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Addiction | 10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Page: 20.0 |
yes | likely (co-administration study) Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine Page: 20.0 |
||
Page: 20.0 |
yes | likely (co-administration study) Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine Page: 20.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12388652/ Page: 5.0 |
PubMed
Title | Date | PubMed |
---|---|---|
[Meperidine (pethidine) outdated as analgesic in acute pancreatitis]. | 2000 Apr 1 |
|
[Condition of patients after surgical wisdom tooth extraction under general anesthesia with different premedication variants--a prospective study based on a post-anesthesia questionnaire]. | 2001 |
|
Single-dose dipyrone for acute postoperative pain. | 2001 |
|
Analgesic efficacy of tramadol 2 mg kg(-1) for paediatric day-case adenoidectomy. | 2001 Apr |
|
Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review. | 2001 Aug |
|
Intrathecal pethidine as sole anaesthetic agent for operative procedures of the lower limb, inguinal area and perineum. | 2001 Dec |
|
Renal colic and recurrent urinary calculi. Management and prevention. | 2001 Jan |
|
Meperidine--a liability. | 2001 Jan |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
Sensitive determination of pethidine in body fluids by surface ionization organic mass spectrometry. | 2001 Jul 5 |
|
[Evaluation of analgesia after cesarean section]. | 2001 Jul-Aug |
|
Post operative pain therapy: a survey of prescribing patterns and adequacy of analgesia in Ibadan, Nigeria. | 2001 Mar |
|
Influence of doxepin used in preemptive analgesia on the nociception in the perioperative period. Experimental and clinical study. | 2001 May-Jun |
|
Ipsilateral dislocation of the shoulder and elbow. | 2001 Nov |
|
Clinical experience and results of ESWL treatment for 3,093 urinary calculi with the Storz Modulith SL 20 lithotripter at the Singapore general hospital. | 2002 |
|
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing. | 2002 |
|
A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery. | 2002 |
|
A placebo-controlled, randomized trial of droperidol versus metoclopramide for outpatients undergoing gynecological laparoscopy under conscious sedation. | 2002 Apr |
|
Laparoscopic hysterectomy versus abdominal hysterectomy: a controlled study of clinical and functional outcomes. | 2002 Aug |
|
Selegiline: a second look. Six years later: too risky in Parkinson's disease. | 2002 Aug |
|
Synergistic sedation with midazolam and propofol versus midazolam and pethidine in colonoscopies: a prospective, randomized study. | 2002 Aug |
|
Leptospirosis: skin wounds and control strategies, Thailand, 1999. | 2002 Dec |
|
A comparison of patient-controlled analgesia administered by the intravenous or intranasal route during the early postoperative period. | 2002 Jan |
|
Use of meperidine in patient-controlled analgesia and the development of a normeperidine toxic reaction. | 2002 Jan |
|
An outbreak of community-acquired foodborne illness caused by methicillin-resistant Staphylococcus aureus. | 2002 Jan |
|
Vitamin K and childhood cancer: analysis of individual patient data from six case-control studies. | 2002 Jan 7 |
|
The management of metastatic bone pain in a developing country: the role of radiotherapy as an adjunct to weak opioids. | 2002 Jan-Feb |
|
Mini cholecystectomy now a day stay surgery: anaesthetic management with multi modal analgesia. | 2002 Jul |
|
A thermal threshold testing device for evaluation of analgesics in cats. | 2002 Jun |
|
Intra-arterial injection of metoclopramide, midazolam, propofol and pethidine. | 2002 Jun |
|
Double-blind, randomized trial comparing Harmonic Scalpel hemorrhoidectomy, bipolar scissors hemorrhoidectomy, and scissors excision: ligation technique. | 2002 Jun |
|
Treatment patterns of isolated benign headache in US emergency departments. | 2002 Mar |
|
Improved procedure of colonoscopy under accompanying music therapy. | 2002 Mar 28 |
|
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial. | 2002 May |
|
Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study. | 2002 May 16 |
|
Plication darn for the repair of inguinal hernia. A university hospital experience. | 2002 Nov |
|
Characterisation of silent and active genes for a variable large protein of Borrelia recurrentis. | 2002 Oct 14 |
|
Two in one: patient-controlled epidural analgesia (PCEA) to prevent erection and control pain in adult hypospadias-surgery patients. | 2002 Sep |
|
Can ketamine potentiate the analgesic effect of epidural morphine, preincisional or postincisional administration? | 2002 Sep |
|
Comparison of colonoscopies performed under sedation with propofol or with midazolam or without sedation. | 2003 |
|
Demographics, assessment and management of pain in the elderly. | 2003 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/meperidine.html
Oral: 50 to 100 mg every 4 hours as needed.
IV,IM,subcutaneously: 25 to 100 mg every 4 hours as needed.
Continuous IV: 15 to 35 mg/hr.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886612
Pethidine's stimulant action on the 22-day pregnant rat isolated uterus does not involve receptors sensitive to methysergide and is unlikely to involve the synthesis and release of endogenous prostaglandins. Maximal stimulant response occurred with 40 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 10:02:57 GMT 2025
by
admin
on
Wed Apr 02 10:02:57 GMT 2025
|
Record UNII |
9E338QE28F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02AG03
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
WHO-ATC |
N02AB72
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
LIVERTOX |
NBK548764
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
NDF-RT |
N0000175690
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
DEA NO. |
9230
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
WHO-ATC |
N02AB52
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
NDF-RT |
N0000175684
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
WHO-VATC |
QN02AB72
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
WHO-VATC |
QN02AB02
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
WHO-ATC |
N02AB02
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
WHO-VATC |
QN02AB52
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
||
|
WHO-ATC |
N02AG03
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9023253
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
6754
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | RxNorm | ||
|
57-42-1
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
100000082223
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
7221
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
411
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
200-329-1
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
PETHIDINE
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
DB00454
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
Meperidine
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
4058
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
CHEMBL607
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
D008614
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
C71632
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
9E338QE28F
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
9E338QE28F
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
3116
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
SUB09738MIG
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
m7186
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
1690
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY | |||
|
6754
Created by
admin on Wed Apr 02 10:02:57 GMT 2025 , Edited by admin on Wed Apr 02 10:02:57 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
DERIVATIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC |
|
||